The so-called "four horsemen" have helped power the Nasdaq to new records. Of those tech leaders, one name stood out for two analysts.» Read More
Channing Smith, portfolio manager at Capital Advisors Growth Fund, told CNBC that Apple is no longer the opportunity it once was.
Bill Gross, Janus Capital Group discusses his take on negative yields and debt.
Channing Smith, Capital Advisers Growth Fund discusses his take on Apple.
Despite "pedestrian" returns, hedge funds are on track to surpass $3 trillion in assets this year, according to a new survey.
David Rolfe, RiverPark Wedgewood Funds discusses his stake in Berkshire Hathaway.
The USDA says beef prices will rise 5-6 percent for the whole year, which is twice the overall rate of food inflation, reports CNBC's Jane Wells.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations.
CNBC's Jon Fortt reports live from the GSMA Mobile World Congress in Barcelona, Spain and touches on the key takeaways.
CNBC's Jackie DeAngelis tracks oil's mixed action into the close. Iranian comments about a potential nuclear deal put downward pressure on crude.
In Monday's "Power Rundown," CNBC's Julia Boorstin, weighs in on ISIS threatening Twitter, and Samsung releasing the latest version of the Galaxy with a new curved screen.
Hedge funds are on track to top $3 trillion in assets this year. Barry Bausano, Deutsche Bank, discusses what's driving the healthy growth.
Former Federal Reserve Chair Ben Bernanke spoke out on opposing the audit the Fed bill.
Janus Capital's Bill Gross on Monday said the Nasdaq hitting 5,000 represents "a little bit of a bubble."
CNBC's Bertha Coombs checks out which sectors are going strong and those that continue to lag.
Holders of senior debt in an Austrian bank have found out they will lose money, and thousands mourned the assassination of Putin critic Boris Nemtsov, reports CNBC's Michelle Caruso-Cabrera.
Amgen's cancer drug Kyprolis demonstrated positive results in a study against Takeda's Velcade. Dr. Sean Harper, Amgen, discusses the benefit risk equation for both drugs.
Finding value in the market after the Nasdaq briefly touched the 5,000 mark, with Brian Belski, BMO Capital Markets, and Zachary Karabell, Envestnet Global Strategy head.
CNBC's Melissa Lee compares Nasdaq valuations from March 2000 to today.
CNBC's Dominic Chu reports on which stocks are leading gains in the Nasdaq Composite.
Ron Insana says Congress should not be auditing the Fed. Period.